SAN ANTONIO, Sept. 16, 2011 /PRNewswire/ — Aperion Biologics,
Inc. announced today that the company will be presenting at the
2011 UBS Global Life Sciences Conference at the Grand Hyatt New
York on Wednesday, September 21, 2011 at 3:00 PM (EDT).
Daniel Lee, Chief Executive Officer, is scheduled to present an
overview of the Company’s unique technology, clinical progress and
plans for commercialization.
Interested parties may listen to the live webcast and view a
copy of the slide presentations by visiting the “News/Events”
section of the Company’s web site at www.aperionbiologics.com.
About Aperion Biologics, Inc.
Aperion Biologics, Inc., located in San Antonio, Texas, is a
privately owned, clinical-stage medical device company addressing
the need for alternatives to human-based grafts with animal-based
tissue technology. Aperion developed and patented a technique to
make animal tissues compatible for challenging human applications.
The core platform technology utilizes the Company’s proprietary
Z-Process™, which removes the key carbohydrate antigens from
animal tissues followed by a unique conversion process that both
stabilizes and sterilizes the tissue without affecting its
biomechanical or biological properties. This creates functioning
scaffolds capable of remodeling into healthy tissue. Aperion’s
Z-Process™ is applicable to a variety of tissues used in
orthopaedic, cardiovascular, plastic, dermatologic, general and
other surgical specialties. The company’s lead product for ligament
reconstruction procedures, the Z-Lig ACLR Device, is currently in
clinical investigation and not commercially approved for sale in
the United States or other markets.